Skip to main content
. 2014 Mar 20;2014:137304. doi: 10.1155/2014/137304

Table 3.

Concomitant diseases in HER2-positive patients without adjuvant trastuzumab treatment.

Premenopausal Postmenopausal All patients
Concomitant diseases, n (%) 35 (14.8%) 202 (85.2%) 237 (100.0%)
 Cardiopulmonary 12/35 (34.3%) 126/202 (62.4%) 138/237 (58.2%)
 Gastrointestinal/hepatic/renal 10/202 (5.0%) 10/237 (4.2%)
 Metabolic 7/35 (20.0%) 22/202 (10.9%) 29/237 (12.2%)
 Mental 6/35 (17.1%) 15/202 (7.4%) 21/237 (8.9%)
 Others 10/35 (28.6%) 29/202 (14.4%) 39/237 (16.5%)